These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9216823)

  • 21. CA-50 and CA-19.9 as tumour markers: which is preferable?
    Maréchal F; Berthiot G; Legrand MG; Larbre H; Cattan A; Deltour G
    Anticancer Res; 1990; 10(4):977-82. PubMed ID: 2382997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Gastrointestinal cancer].
    Takahashi Y
    Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J; Genolla J; Ruibal A
    Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies.
    Louhimo J; Finne P; Alfthan H; Stenman UH; Haglund C
    Anticancer Res; 2002; 22(3):1759-64. PubMed ID: 12168865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum CA 19-9, SLX, STN and CEA levels of the peripheral and the draining venous blood in gastric cancer.
    Imada T; Rino Y; Takahashi M; Hatori S; Shiozawa M; Amano T; Kondo J
    Hepatogastroenterology; 1999; 46(27):2086-90. PubMed ID: 10430402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [CEA, CA 19.9 and CA 195 in patients with colorectal carcinoma. ROC analysis].
    Vallejo J; Torres-Avisbal M; Contreras P; Rodríguez-Liñán M; Rebollo A; González F; Benítez A; Infante J; Mateo A
    Rev Esp Med Nucl; 1999 Aug; 18(4):281-6. PubMed ID: 10481111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative analysis of CA 242 and CA 19-9 serum tumor markers in colorectal cancer patients. A longitudinal evaluation.
    Spila A; Ferroni P; Cosimelli M; D'Alessandro R; Abbolito MR; Mariotti S; Aloe S; Carone MD; Graziano F; Tedesco M; Martini F; Mancini R; Stigliano V; Roselli M; Guadagni F
    Anticancer Res; 2001; 21(2B):1263-70. PubMed ID: 11396197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atypical courses of serum tumor markers--4 case reports.
    Klapdor R; Bahlo M; Babinski A
    Anticancer Res; 2003; 23(2A):845-50. PubMed ID: 12820311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of some tumor markers in differential diagnosis of ovarian tumor.
    Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
    Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Determination of the tumor marker CA 72-4 in gastric carcinoma].
    Martín-Pérez E; Fernández-Arjona M; Baza B; Villanueva C; Larrañaga E; Serrano PA; Clerigué A
    Rev Esp Enferm Dig; 1993 Feb; 83(2):92-6. PubMed ID: 8471361
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Developing a hospital-based high risk scoring model and screening strategy for pancreatic cancer].
    Deng RX; Lu XH; Wang L; Li H; Qian JM; Yang AM; Zhong SX; Guo XZ; Zhou L; Wu X; Yang XO; Jiang WJ
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(29):2038-42. PubMed ID: 16313796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
    Markocka-Maczka K
    Wiad Lek; 2003; 56(11-12):537-40. PubMed ID: 15058160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection.
    Marrelli D; Roviello F; De Stefano A; Fotia G; Giliberto C; Garosi L; Pinto E
    J Am Coll Surg; 2004 Jan; 198(1):51-8. PubMed ID: 14698311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y; Tapuria N; Kirmani N; Davidson BR
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.
    Schneider J; Schulze G
    Anticancer Res; 2003; 23(6D):5089-93. PubMed ID: 14981971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical significance of serum CA 125 values in patients with gastric cancers--especially correlation with peritonitis carcinomatosa].
    Takahashi Y; Suga T; Mai M
    Gan To Kagaku Ryoho; 1992 Jul; 19(7):975-9. PubMed ID: 1626954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Advances regarding tumor markers in bladder cancer].
    Moreno Sierra J; Chicharro Almarza GJ; Torronteras Santiago JM; Ortega Heredia MD; Maestro de las Casas ML; Silmi Moyano A; Resel Estévez L
    Actas Urol Esp; 1997 Mar; 21(3):195-205. PubMed ID: 9324884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The usefulness of the carbohydrate antigen CA-50 in the prognosis of transitional-cell bladder carcinomas].
    Moreno Sierra J; Blanco Jímenez E; Silmi Moyano A; Ortega Heredia MD; Páramo González P; Maestro de las Casas ML; Fernández Lucas C; Ramírez Fernández JC; Luengo Alpuente S; Gómez Vegas A
    Arch Esp Urol; 1993 Nov; 46(9):775-8. PubMed ID: 8304791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.